Lantern Pharma Statistics

Total Valuation

Lantern Pharma has a market cap or net worth of $47.45 million. The enterprise value is $9.28 million.

Market Cap	47.45M
Enterprise Value	9.28M

Important Dates

The next estimated earnings date is Wednesday, August 7, 2024, after market close.

Earnings Date	Aug 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Lantern Pharma has 10.76 million shares outstanding. The number of shares has decreased by -1.05% in one year.

Shares Outstanding	10.76M
Shares Change (YoY)	-1.05%
Shares Change (QoQ)	-0.51%
Owned by Insiders (%)	14.75%
Owned by Institutions (%)	22.27%
Float	7.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.33
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.98, with a Debt / Equity ratio of 0.01.

Current Ratio	9.98
Quick Ratio	n/a
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -41.20% and return on invested capital (ROIC) is -53.74%.

Return on Equity (ROE)	-41.20%
Return on Assets (ROA)	-38.40%
Return on Capital (ROIC)	-53.74%
Revenue Per Employee	n/a
Profits Per Employee	-$834,980
Employee Count	21
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -4.55% in the last 52 weeks. The beta is 1.55, so Lantern Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.55
52-Week Price Change	-4.55%
50-Day Moving Average	5.29
200-Day Moving Average	4.93
Relative Strength Index (RSI)	44.72
Average Volume (20 Days)	65,721

Short Selling Information

The latest short interest is 308,876, so 2.87% of the outstanding shares have been sold short.

Short Interest	308,876
Short Previous Month	333,513
Short % of Shares Out	2.87%
Short % of Float	3.89%
Short Ratio (days to cover)	3.70

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-19.32M
Pretax Income	-17.53M
Net Income	-17.53M
EBITDA	-17.36M
EBIT	-17.53M
Earnings Per Share (EPS)	-$1.63

Full Income Statement

Balance Sheet

The company has $38.36 million in cash and $193,584 in debt, giving a net cash position of $38.16 million or $3.55 per share.

Cash & Cash Equivalents	38.36M
Total Debt	193,584
Net Cash	38.16M
Net Cash Per Share	$3.55
Equity (Book Value)	35.77M
Book Value Per Share	3.32
Working Capital	35.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$13.66 million and capital expenditures -$12,075, giving a free cash flow of -$13.67 million.

Operating Cash Flow	-13.66M
Capital Expenditures	-12,075
Free Cash Flow	-13.67M
FCF Per Share	-$1.27

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lantern Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.05%
Shareholder Yield	1.05%
Earnings Yield	-36.96%
FCF Yield	-28.81%

Analyst Forecast

The average price target for Lantern Pharma is $11.00, which is 149.43% higher than the current price. The consensus rating is "Buy".

Price Target	$11.00
Price Target Difference	149.43%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3